This post is from a suggested group
Cell and Gene Therapy CDMO Market: Driving Innovation in Advanced Biologics
The Cell and Gene Therapy CDMO Market has emerged as a critical segment within the biopharmaceutical industry, fueled by the rising demand for personalized medicine and advanced biologics. Contract Development and Manufacturing Organizations (CDMOs) play a pivotal role in supporting biopharmaceutical companies by providing end-to-end solutions, including process development, scale-up, and commercial manufacturing of cell and gene therapies. These therapies, which include CAR-T therapies, gene editing, and viral vector-based treatments, are revolutionizing the treatment of rare genetic disorders, cancers, and other chronic conditions.
One of the primary drivers of market growth is the increasing number of clinical trials in the cell and gene therapy space. Biopharmaceutical companies are increasingly outsourcing manufacturing and development tasks to CDMOs to reduce costs, accelerate time-to-market, and mitigate risks associated with complex production processes. Additionally, technological advancements in viral vector manufacturing, gene editing techniques,…
